…at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...

ABOUT HANSA BIOPHARMA

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. The Company has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S.

BROAD PIPELINE IN TRANSPLANTATION AND AUTOIMMUNE DISEASES

Candidate	Indication	Research/ Preclinical	Phase 1	Potentially Pivotal program/ Phase 2	Phase 3	Marketing Authorization	Marketed
Imlifidase	**EU** Kidney transplantation in highly sensitized patients [1,2]	Completed	Completed	Completed	Completed	Completed	*)
	US Kidney transplantation in highly sensitized patients [1,2]	Completed	Completed	Completed	Ongoing		
	Anti-GBM antibody disease (investigator-initiated study)	Completed	Completed	Ongoing			
	Antibody mediated kidney transplant rejection (AMR)	Completed	Completed	Ongoing			
	GBS (Guillain Barre Syndrome)	Completed	Completed	Ongoing			
	Limb-Girdle (LGMD) & Duchenne (DMD) (Pre-treatment ahead of gene therapy with Sarepta)	Ongoing					
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology	Ongoing					
EnzE	Cancer immunotherapy	Ongoing					

Completed
Ongoing

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
3 Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund
*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. A post-approval study will commence in parallel with the launch

STRATEGIC PRIORITIES

1	2	3
Advance platform in new indications and therapeutic areas	**Commercialize** Idefirix® in first markets and indications	**Build** organizational capablitlies and expand technology platform

ANTICIPATED FUTURE MILESTONES



Updated 2020-10-22

Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund, Sweden
www.hansabiopharma.com

HANSA BIOPHARMA

COMPANY FACTS

Founded	2007
Stock Exchange	NASDAQ Stockholm (HNSA)
Headquarter	Lund, Sweden
Operations	Europe and the US
Employees	~100 (~2/3 in R&D)
Key Executives	Ulf Wiinberg, Chairman
	Søren Tulstrup, President & CEO
	Donato Spota, SVP & CFO
	Christian Kjellman, SVP & CSO/COO

MARKET DATA (Q1 2021)

Market Cap	USD ~1 bn	
52 Week Range	SEK 78-289	
Avg. Daily Turnover	vol. 381k shares	
Shares Outstanding	45m	
Top 5 Shareholders	Redmile Group	10.4%
	NXT2B	4.9%
	Handelsbanken Fonder	4.6%
	Invesco	4.4%
	AP4	4.4%

STOCK CHART (1Y)

KEY FINANCIALS

SEKm	2018	2019	2020
Revenue	3m	3m	6m
R&D cost	-155m	-193m	-227m
Net loss	-258m	-360m	-421m
Cash & Short investment	858m	601m	1,378m
Operating Cash Flow	-205m	-335m	-290m
Employees	52	74	87

** Unaudited*

CALENDAR

April 28, 2021	Redeye Orphan Drugs Event
May 5, 2021	Kempen Life Sciences Conference
May 12, 2021	Annual General Meeting 2021
May 19, 2021	RBC Global Healthcare Conference
June 1, 2021	Jefferies Healthcare Conference
July 15, 2021	Interim report for Jan-Jun 2021
Aug 25, 2021	Handelsbanken Life Science Seminar
Sep 1, 2021	Pareto Healthcare Conference
Oct 21, 2021	Interim report for Jan-Sep 2021

CONTACTS

Klaus Sindahl
Head of Investor Relations
M: +46(0)709-298 269
klaus.sindahl@hansabiopharma.com

Katja Margell
Head of Corp. Comms.
M: +46(0)768-198 326
katja.margell@hansabiopharma.com

IMLIFIDASE – A NOVEL APPROACH TO ELIMINATING PATHOGENIC IgG

Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection

Imlifidase, a unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Imlifidase inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



OUR BUSINESS MODEL

Growth engine

Leveraging our proprietary antibody cleaving enzyme technology

Value chain

We are controlling the full value chain



Commercialization

Build-up of franchises	Indications and therapies	Multiple income streams
Own commercial infrastructure	Transplantation	Revenue / sales
	Autoimmune diseases	Upfront payments
Partnership strategy	Gene therapy	Milestone payments
	Oncology	Royalties

Evolution into a fully integrated biopharmaceutical company

POTENTIAL INDICATION UNIVERSE



* US: Study protocol submitted June 2020, study expected to be initiated H1 2021. The new clinical study could support BLA submission by 2023